| 42.2 -0.03 (-0.07%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 49.62 | 1-year : | 57.96 |
| Resists | First : | 42.49 | Second : | 49.62 |
| Pivot price | 42.14 |
|||
| Supports | First : | 42.09 | Second : | 41.84 |
| MAs | MA(5) : | 42.22 |
MA(20) : | 42.17 |
| MA(100) : | 41.66 |
MA(250) : | 38.16 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 59.3 |
D(3) : | 60.4 |
| RSI | RSI(14): 51.6 |
|||
| 52-week | High : | 45.75 | Low : | 24.69 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TARO ] has closed below upper band by 33.7%. Bollinger Bands are 85.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 53 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 42.24 - 42.53 | 42.53 - 42.76 |
| Low: | 41.58 - 41.87 | 41.87 - 42.1 |
| Close: | 41.79 - 42.24 | 42.24 - 42.62 |
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
Wed, 24 Apr 2024
How To Trade (TARO) - Stock Traders Daily
Mon, 22 Apr 2024
TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC ... - Business Wire
Fri, 19 Apr 2024
Taro to hold meetings for approval of merger with Sun Pharmaceutical Industries - Drug Store News
Fri, 05 Apr 2024
Bausch, Sun's Taro Settle Patent Clash on Duobrii Psoriasis Drug - Bloomberg Law
Fri, 19 Jan 2024
Sun Finally Buys Remaining Taro Shares in $348M Takeover - BioSpace
Thu, 18 Jan 2024
Sun Pharma to buy remaining stake in Taro Pharma for $347.8 million. Details here | Mint - Mint
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 38 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 78.4 (%) |
| Held by Institutions | 13.4 (%) |
| Shares Short | 40 (K) |
| Shares Short P.Month | 59 (K) |
| EPS | 1.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 47.33 |
| Profit Margin | 7.4 % |
| Operating Margin | 10.6 % |
| Return on Assets (ttm) | 1 % |
| Return on Equity (ttm) | 2.6 % |
| Qtrly Rev. Growth | 12.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 16.25 |
| EBITDA (p.s.) | 1.83 |
| Qtrly Earnings Growth | 178.1 % |
| Operating Cash Flow | 143 (M) |
| Levered Free Cash Flow | 81 (M) |
| PE Ratio | 34.59 |
| PEG Ratio | -3 |
| Price to Book value | 0.89 |
| Price to Sales | 2.59 |
| Price to Cash Flow | 11.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|